The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings.
 
Raajit Rampal
Honoraria - Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Disc Medicine; Galecto; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia; Promedior; SERVIER; Sierra Oncology; Stemline Therapeutics; Sunimoto Dainippon; Zentalis
Research Funding - Constellation Pharmaceuticals; Ryvu Therapeutics; Stemline Therapeutics; Zentalis
Travel, Accommodations, Expenses - Incyte; Sierra Oncology
 
Samantha Eiffert
Employment - Bristol Myers Squibb; IntegraConnect
 
Michael Marrone
Employment - SOBI; Team Health (I)
 
Lisa Morere
Employment - IntegraConnect
 
Abiola Oladapo
Employment - SOBI
Stock and Other Ownership Interests - Biogen; Takeda
Research Funding - SOBI
Travel, Accommodations, Expenses - SOBI
Other Relationship - SOBI
 
Anubhav Sharma
Employment - IntegraConnect
 
Purvi Suthar
Employment - SOBI
Travel, Accommodations, Expenses - SOBI
Other Relationship - Received payment of unvested equity awards as a company employee as part of an overall compensation package from CTI BioPharma Corp., a Sobi Company
 
Anupama Vasudevan
Employment - IntegraConnect; IntegraConnect
Stock and Other Ownership Interests - McKesson
 
Michael Vredenburg
Employment - SOBI
 
John Mascarenhas
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Disc Medicine; Galecto; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Keros Therapeutics; Merck; MorphoSys; MorphoSys; Novartis; Pharmaessentia; Roche/Genentech; SOBI; Sumitomo Pharma Oncology
Research Funding - Abbvie (Inst); Celgene/Bristol-Myers Squibb (Inst); Disc Medicine; Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); MorphoSys; Novartis (Inst); Pharmaessentia (Inst); SOBI